Medication interactions

This study is an open-label drug-drug interaction (DDI) study of ZYN002 transdermal gel and multiple drugs.

The goal of this longitudinal mixed-methods study is to investigate caregiver strain, family processes and health outcomes after youth psychiatric inpatient treatment. Caregivers of youth who received inpatient treatment for mental health problems will complete a survey at three timepoints (baseline, 3- and 6- month followup) reporting on youth outcomes, caregiver well-being, and family processes. Qualitative interviews on caregivers' challenges, needs, and resources around the return to home care are conducted with a subsample (target n = 10) of participants.
The main research questions (RQs) are:
RQ 1: Do family processes contribute to youth mental health outcomes after discharge from inpatient treatment? RQ 1a: What family-level risk factors predict youth readmission to inpatient treatment? RQ 1b: Do family processes predict youth mental health trajectories over time? RQ 2: Is there a reciprocal relationship between youth mental health problems and caregiver burden? RQ 2a: Do family processes mediate the association between caregiver burden and youth mental health problems? RQ 3: How do caregivers experience their children's return to home care? RQ 3a: What challenges and needs do caregivers report? RQ 3b: What types of follow-up services do families receive and/or have access to? RQ 3c: How do caregivers cope with ongoing difficulties in the post-discharge period?

Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.
There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.